The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis
Open accessAbstract
Background: There is little information about the effect of infliximab on the clinical course of liver disease in Crohn’s disease patients with concomitant hepatitis B virus (HBV) infection. Theoretically, immunosuppression induced by infliximab will facilitate viral replication which could be followed by a flare or exacerbation of disease when therapy is discontinued. There are no specific recommendations on surveillance and treatment of HBV before infliximab infusion. Two cases of severe hepatic failure related to infliximab infusions have been described in patients with rheumatic diseases. Patients and methods: Hepatitis markers (C and B) and liver function tests were prospectively determined to 80 Crohn’s disease patients requiring infliximab infusion in three hospitals in Spain. Results: Three Crohn’s disease patients with chronic HBV infection were identified. Two of the three patients with chronic HBV infection suffered severe reactivation of chronic hepatitis B after withdrawal of infliximab therapy and one died. A third patient, who was treated with lamivudine at the time of infliximab therapy, had no clinical or biochemical worsening of liver disease during or after therapy. From the remaining 80 patients, six received the hepatitis B vaccine. Three patients had antibodies to both hepatitis B surface antigen (anti-HBs) and hepatitis B core protein (anti-HBc) with normal aminotransferase levels, and one patient had positive anti-hepatitis C virus (HCV) antibodies, negative HCV RNA, and normal aminotransferase levels. Except for the patients with chronic HBV infection, no significant changes in hepatic function were detected. Conclusions: Patients with Crohn’s disease who are candidates for infliximab therapy should be tested for hepatitis B serological markers before treatment and considered for prophylaxis of reactivation using antiviral therapy if positive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perrillo, R. P. (2001) · Gastroenterology · doi:10.1053/gast.2001.22461 · Cited by 421
Management of chronic hepatitis B
Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00431-2 · Cited by 257
Marusawa, H., Uemoto, S., Hijikata, M., Ueda, Y., Tanaka, K., Shimotohno, K., & Chiba, T. (2000) · Hepatology · doi:10.1002/hep.510310232 · Cited by 238
Ostuni, P., Botsios, C., Punzi, L., Sfriso, P., & Todesco, S. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.7.686 · Cited by 217
Michel, M., Duvoux, C., Hézode, C., & Cherqui, D. (2003) · PubMed · Cited by 201
Lau, G. K. K., He, M., Fong, D., Bartholomeusz, A., Au, W., Lie, A. K. W., LOCARNINI, S. A., & Liang, R. H. S. (2002) · Hepatology · doi:10.1053/jhep.2002.35068 · Cited by 192
Hepatitis B and C Virus Infection in Crohn's Disease
Biancone, L., Pavía, M., Blanco, G. D. V., Renata D'Incà, Castiglione, F., Nigris, F. D., Doldo, P., Cosco, C., Vavassori, P., Bresci, G., et al. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200111000-00002 · Cited by 103
Use of anti-tumour necrosis factor agents in inflammatory bowel disease
Schreiber, S., Campieri, M., Colombel, J., van Deventer, S. J. H., Feagan, B., Fedorak, R. N., Forbes, A., Gassull, M. À., Jp, G., van Hogezand, R. A., et al. (2001) · International Journal of Colorectal Disease · doi:10.1007/s003840100285 · Cited by 49
Holtmann, M. H., Galle, P. R., & Neurath, M. F. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07245.x · Cited by 37
Cited by
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Management of hepatitis B: Summary of a clinical research workshop†
Hoofnagle, J. H., Doo, E., Liang, T. J., Fleischer, R., & Lok, A. S. F. (2007) · Hepatology · doi:10.1002/hep.21627 · Cited by 628
Metadata
- Authors
- Esteve, M., Saro, C., González-Huix, F., Suarez, F., Forné, M., & Viver, J. M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2004-08-11
- Volume
- 53
- Issue
- 9
- Pages
- 1363-1365
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2117905220
- Cited by
- 467
- References
- 9
- FWCI
- 18.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. https://app.cochat.ai/papers/10.1136/gut.2004.040675
- The paper
- Esteve, M., Saro, C., González-Huix, F., Suarez, F., Forné, M., & Viver, J. M. (2004). Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut. https://doi.org/10.1136/gut.2004.040675
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.